Ionis (NASDAQ: IONS) director exercises 10,111 options and sells shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Ionis Pharmaceuticals director Joseph Klein III exercised a non-qualified stock option for 10,111 shares of common stock at an exercise price of $47.11 per share and, on the same date, sold 10,111 shares in open-market transactions under a pre-arranged Rule 10b5-1 Trading Plan. The sales consisted of 8,680 shares at a weighted-average price of $73.3530 and 1,431 shares at a weighted-average price of $74.4474. Following these transactions, Klein held 11,014 shares of Ionis common stock directly. An additional 100 shares are held indirectly by his son, and Klein disclaims beneficial ownership of those shares.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 10,111 shares ($743,238)
Net Sell
5 txns
Insider
KLEIN JOSEPH III
Role
null
Sold
10,111 shs ($743K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 10,111 | $0.00 | -- |
| Exercise | Common Stock | 10,111 | $47.11 | $476K |
| Sale | Common Stock | 8,680 | $73.353 | $637K |
| Sale | Common Stock | 1,431 | $74.4474 | $107K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 0 shares (Direct, null);
Common Stock — 21,125 shares (Direct, null);
Common Stock — 100 shares (Indirect, by Son)
Footnotes (1)
- Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on November 25, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.95 to $73.64 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.07 to $74.92 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4. The reporting person disclaims beneficial ownership of all securities held by his son, and this report should not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Key Figures
Options exercised: 10,111 shares
Exercise price: $47.11 per share
Shares sold (block 1): 8,680 shares at $73.3530
+4 more
7 metrics
Options exercised
10,111 shares
Non-qualified stock option for common stock exercised at $47.11
Exercise price
$47.11 per share
Exercise price of non-qualified stock option for 10,111 shares
Shares sold (block 1)
8,680 shares at $73.3530
Open-market sale of common stock on 2026-05-01
Shares sold (block 2)
1,431 shares at $74.4474
Open-market sale of common stock on 2026-05-01
Net shares sold
10,111 shares
Net sell shares from transactionSummary
Direct holdings after
11,014 shares
Total Ionis common stock held directly after transactions
Indirect holdings by son
100 shares
Shares held by son; beneficial ownership disclaimed by Klein
Key Terms
Rule 10b5-1 Trading Plan, Non-Qualified Stock Option, weighted average price, beneficial ownership, +1 more
5 terms
Rule 10b5-1 Trading Plan financial
"Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy) with 10,111 underlying shares"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
beneficial ownership financial
"The reporting person disclaims beneficial ownership of all securities held by his son"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
Section 16 regulatory
"not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16"
Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.
FAQ
What insider transactions did Ionis (IONS) director Joseph Klein report on this Form 4?
Joseph Klein reported exercising options for 10,111 Ionis shares and selling 10,111 shares of common stock in open-market transactions. The activity reflects an exercise-and-sell pattern, leaving his overall direct share ownership at 11,014 Ionis shares after the reported transactions.
Were Joseph Klein’s Ionis (IONS) stock sales part of a Rule 10b5-1 trading plan?
Yes, the Form 4 states that the shares were sold pursuant to a Rule 10b5-1 Trading Plan adopted by Joseph Klein. Such plans pre-schedule trades, indicating the timing of these sales was arranged in advance rather than based on real-time market information or personal discretion.
What stock option activity did Joseph Klein report for Ionis (IONS) on this Form 4?
Klein exercised a non-qualified stock option covering 10,111 Ionis common shares at an exercise price of $47.11 per share. After this exercise, the option position reported in the filing shows zero remaining derivative shares, meaning that particular option grant was fully exercised.